Advancing Genomics Technologies for Health and Life Sciences

Canada's Michael Smith Genome Sciences Centre (GSC), a provincial program within the Provincial Health Services Authority (PHSA), is a recognized international leader in genomics, bioinformatics, and genome technology innovation. By developing and deploying cutting-edge sequencing and computational platforms, the GSC supports breakthrough research across cancer, rare and infectious diseases, and the broader life sciences. Our work enables earlier diagnosis, novel therapeutic approaches, and transformative applications of genomics to improve human health and environmental resilience—delivering both social and economic impact through science.

Partner with the GSC

The Genome Sciences Centre (GSC) is here to support your research. We collaborate with investigators to design robust experiments, process complex and high-value biological samples, and provide advanced sequencing and bioinformatics services—all with the goal of making genomics accessible and impactful for the global scientific community.

Explore our technology platforms and service offerings, and if you are interested in collaborating or have questions, please complete our contact form or email us at info@bcgsc.ca.

The GSC is ISO/IEC 27001 certified for information security management, ensuring the highest standards in data protection and confidentiality.

Scientific Research

The Genome Sciences Centre (GSC) brings together faculty members with expertise across genomics, computational biology, cancer, disease biology, and the broader life sciences. Our research harnesses the power of genomics to improve human health—through better diagnosis, treatment, and disease prevention—and to advance the broader application of genomics across sectors that support a more sustainable and resilient future.

Translational Genomics and Clinical Integration

The Genome Sciences Centre (GSC) is distinguished by its strong integration of research and clinical practice, fostering close collaboration between scientists and clinicians to enable real-time translational impact. Through the Personalized OncoGenomics (POG) program, the GSC applies whole genome and transcriptome sequencing to guide therapeutic decision-making for patients with advanced cancers.
In addition to its research mandate, the GSC is accredited by the College of American Pathologists (CAP) and the Diagnostic Accreditation Program (DAP) to perform clinical genomic panel testing, supporting precision medicine initiatives across British Columbia.

Questions?

We’re here to help - reach us at info@bcgsc.ca.

News

Mar 05, 2025

GSC to Collaborate on Five Projects for the Canadian Precision Health Initiative

The GSC is proud to announce its collaboration on five groundbreaking projects as part of the Canadian Precision Health Initiative (CPHI). This ambitious national effort, launched today in Ottawa by the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, represents an $81-million investment from the Government of Canada through Genome Canada.

Jan 14, 2025

Dr. Marco Marra appointed as UBC Killam Professor

UBC has announced the appointment of Dr. Marco Marra as one of three new University Killam Professors. The University Killam Professorship—the highest honour UBC can confer on a faculty member—recognizes exceptional teachers and researchers who are leaders in their fields, and who have received international recognition for their achievements.

Marco Marra

Department of Medical Genetics, Faculty of Medicine & Michael Smith Laboratories

Publications

Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19

The Journal of Clinical Investigation
Gundula Povysil, Guillaume Butler-Laporte, Ning Shang, Chen Wang, Atlas Khan, Manal Alaamery, Tomoko Nakanishi, Sirui Zhou, Vincenzo Forgetta, Robert JM Eveleigh, Mathieu Bourgey, Naveed Aziz, Steven JM Jones, Bartha Knoppers, Stephen W Scherer, Lisa J Strug, Pierre Lepage, Jiannis Ragoussis, Guillaume Bourque, Jahad Alghamdi, Nora Aljawini, Nour Albes, Hani M Al-Afghani, Bader Alghamdi, Mansour S Almutairi, Ebrahim Sabri Mahmoud, Leen Abu-Safieh, Hadeel El Bardisy, Fawz S Al Harthi, Abdulraheem Alshareef, Bandar Ali Suliman, Saleh A Alqahtani, Abdulaziz Almalik, May M Alrashed, Salam Massadeh, Vincent Mooser, Mark Lathrop, Mohamed Fawzy, Yaseen M Arabi, Hamdi Mbarek, Chadi Saad, Wadha Al-Muftah, Junghyun Jung, Serghei Mangul, Radja Badji, Asma Al Thani, Said I Ismail, Ali G Gharavi, Malak S Abedalthagafi, J Brent Richards, David B Goldstein, Krzysztof Kiryluk

Proteomic screens for suppressors of anoikis identify IL1RAP as a promising surface target in Ewing sarcoma

Cancer Discovery, 2021
Hai-Feng Zhang, Christopher S Hughes, Wei Li, Jian-Zhong He, Didier Surdez, Amal M El-Naggar, Hongwei Cheng, Anna Prudova, Alberto Delaidelli, Gian Luca Negri, Xiaojun Li, Maj Sofie Orum-Madsen, Michael M Lizardo, Htoo Zarni Oo, Shane Colborne, Taras Shyp, Renata Scopim-Ribeiro, Colin A Hammond, Anne-Chloe Dhez, Sofya Langman, Jonathan Km Lim, Sonia Hy Kung, Amy Li, Anne Steino, Mads Daugaard, Seth J Parker, Ramon I Klein Geltink, Rimas J Orentas, Li-Yan Xu, Gregg B Morin, Olivier Delattre, Dimiter S Dimitrov, Poul H Sorensen
Back to top